Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pazopanib + vinflunine
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Pazopanib + vinflunine is an investigational combination therapy consisting of two small molecule antineoplastic agents. Pazopanib is a second-generation multitargeted tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-α and PDGFR-β), and c-KIT, thereby inhibiting angiogenesis and tumor growth. Vinflunine is a microtubule inhibitor belonging to the vinca alkaloid class, disrupting mitotic spindle formation and cell division. This combination was studied in patients with metastatic transitional cell carcinoma of the urothelium who had failed first-line platinum-containing therapy. In phase I trials, the regimen was poorly tolerated due to significant toxicities such as febrile neutropenia and hepatobiliary disorders; as a result, further development was halted at an early stage[1][2][5].
- Other names
- pazopanib + vinflunine
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)CSF1R (Macrophage colony-stimulating factor receptor)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)TUBB (Tubulin (alpha and beta subunits))VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on pazopanib + vinflunine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pazopanib + vinflunine.